Company Overview of DermTech, Inc.
DermTech International, a molecular diagnostic company, is engaged in developing and marketing gene expression tests to facilitate the diagnosis of dermatologic conditions. The company offers Adhesive Skin Sample Collection Kit, which consists of adhesive patches, instructions for use, a marking pen for lesion outlining, and a pre-addressed and prepaid return shipping pack. Its Adhesive Skin Sample Collection Kit allows for the collection of skin samples with minimal patient discomfort. The company also provides Pigmented Lesion Assay for reducing unnecessary surgical biopsy procedures and enhancing diagnostic accuracy; ribonucleic acid extraction services; and a smart phone based photoinfor...
11099 North Torrey Pines Road
La Jolla, CA 92037
Founded in 1995
Key Executives for DermTech, Inc.
Director of Business Administration
Compensation as of Fiscal Year 2014.
DermTech, Inc. Key Developments
DermTech International Adds Three Members to its Commercialization Team
Jul 8 14
DermTech International announced that it has added three members to its commercialization team. Art Wampole will lead the company's sales effort, Annie Bell will lead the company's marketing strategy, and Mildred Romero will lead the company's reimbursement implementation. Art Wampole was previously the Vice President of Sales at Dermpath Diagnostics. Annie Bell held senior management positions in Sales and Marketing for Ameripath Inc. and was the general manager of Dermpath Diagnostics. Mildred Romero has held senior management positions and led reimbursement development at several innovative diagnostics companies including DexCom Inc. and Pathway Genomics Corporation.
DermTech International Auditor Raises 'Going Concern' Doubt
May 9 14
DermTech International filed its Annual on May 09, 2014 for the period ending Dec 31, 2013. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
DermTech Seeks Acquisitions
May 9 14
DermTech International to seek acquisitions. DermTech International has filed for an initial public offering for $25 million, the proceeds of which will be used to acquire, invest in, or license complementary products, technologies, or businesses although we have no current commitments, understandings, or agreements to do so.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries